---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-048027"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:07:18.940052+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci reports prelim FY2023 revenue $5.7M, cash $97.7M; proposes public offering

## Summary
- Preliminary Q4 revenue ~$0.3M, FY revenue ~$5.7M; operating expenses $120-122M incl $21.3M goodwill impairment.
- Unrestricted cash/short-term investments $97.7M as of Dec 31, 2023.
- Filed preliminary prospectus for underwritten public offering of common stock (undisclosed size).
- 16 Active Programs with partners including AstraZeneca, Almirall, Merck; ABS-101 IND submission planned Q1 2025.
- ABS-101 IND-enabling studies started Feb 2024; Phase 1 potentially H1 2025.

## SEC filing metadata
- accession: 0001193125-24-048027
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000119312524048027/0001193125-24-048027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000119312524048027/d800047d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-048027
- JSON: https://secwatch.observer/filing/0001193125-24-048027.json
- Plain text: https://secwatch.observer/filing/0001193125-24-048027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.